Patents by Inventor Steven R. Williams
Steven R. Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230002475Abstract: This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified ?1-?2 domains of NKG2D ligands.Type: ApplicationFiled: September 13, 2022Publication date: January 5, 2023Applicant: XYPHOS BIOSCIENCES INC.Inventors: Kyle LANDGRAF, Daniel P. Steiger, Steven R. Williams, David W. Martin, JR.
-
Patent number: 11453713Abstract: This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified ?1-?2 domains of NKG2D ligands.Type: GrantFiled: December 4, 2015Date of Patent: September 27, 2022Assignee: XYPHOS BIOSCIENCES INC.Inventors: Kyle Landgraf, Daniel P. Steiger, Steven R. Williams, David W. Martin
-
Patent number: 11117969Abstract: This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified ?1-?2 domains of NKG2D ligands. This application further relates to modified ?1-?2 domains of NKG2D ligands attached to polypeptides, in some embodiments antibodies or fragments of antibodies. This application further relates to antigen-binding peptides derived from light and heavy chain antibody variable domains, which contain two linker regions and a split variable domain.Type: GrantFiled: June 24, 2016Date of Patent: September 14, 2021Assignee: XYPHOS BIOSCIENCES INC.Inventors: Kyle Landgraf, Daniel P. Steiger, Steven R. Williams, David W. Martin, Jr., Dana Gebhart, Tarah Baron
-
Patent number: 10585850Abstract: A method of restoring a file to a previous version of the file, where a current version of the file being available at a local storage location is disclosed. The method includes receiving a request to display a list of captured revisions for a file; displaying a list of captured revisions for said file; receiving a selection from said list indicating a revision of said file to restore; previewing selected revision of said file, wherein said selected revision of said file is received from an Internet storage area network; receiving another selection from said list indicating another revision of said file to restore; previewing selected another revision of said file, wherein said selected another revision of said file is received from a network attached storage location; and restoring selected another revision of said file following the previewing step.Type: GrantFiled: December 15, 2015Date of Patent: March 10, 2020Inventors: Warren Roach, Steven R. Williams, Troy J. Reiber, Steven C. Burdine
-
Patent number: 10331619Abstract: A method for archiving files includes determining when a change in an operating file is imminent, capturing the operating file immediately before the change in the operating file occurs, if the operating file has not already been captured; and capturing the operating file immediately after the change in the operating file has occurred.Type: GrantFiled: October 20, 2017Date of Patent: June 25, 2019Inventors: Warren Roach, Steven R Williams, Troy J Reiber, Steven C Burdine
-
Patent number: 10229123Abstract: A method for archiving files includes determining when a change in an operating file is imminent, capturing the operating file immediately before the change in the operating file occurs, if the operating file has not already been captured; and capturing the operating file immediately after the change in the operating file has occurred.Type: GrantFiled: October 20, 2017Date of Patent: March 12, 2019Inventors: Warren Roach, Steven R Williams, Troy Reiber, Steven C Burdine
-
Publication number: 20160103843Abstract: A method for archiving flies includes determining when a change in an operating file is imminent, capturing the operating file immediately before the change in the operating file occurs, if the operating file has not already been captured; and capturing the operating file immediately after the change in the operating file has occurred.Type: ApplicationFiled: December 15, 2015Publication date: April 14, 2016Inventors: Warren Roach, Steven R. Williams, Troy J. Reiber, Steven C. Burdine
-
Patent number: 9218348Abstract: A method for archiving files includes determining when a change in an operating file is imminent, capturing the operating file immediately before the change in the operating file occurs, if the operating file has not already been captured; and capturing the operating file immediately after the change in the operating file has occurred.Type: GrantFiled: June 24, 2013Date of Patent: December 22, 2015Inventors: Warren Roach, Steven R. Williams, Troy J. Reiber, Steven C. Burdine
-
Patent number: 9079969Abstract: This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their ?1-?2 platform domain, to the intended target cell specifically. The ?1-?2 domain is contiguous with a heterologous ?3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the ?3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified ?3 domain of a MIC protein.Type: GrantFiled: June 20, 2014Date of Patent: July 14, 2015Assignee: AvidBiotics Corp.Inventors: David W. Martin, Jr., Steven R. Williams
-
Publication number: 20150165065Abstract: This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their ?1-?2 platform domain, to the intended target cell specifically. The ?1-?2 domain is contiguous with a heterologous ?3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the ?3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified ?3 domain of a MIC protein.Type: ApplicationFiled: December 5, 2014Publication date: June 18, 2015Applicant: AvidBiotics Corp.Inventors: Kyle LANDGRAF, Daniel P. Steiger, Steven R. Williams, David W. Martin, JR.
-
Publication number: 20140302072Abstract: This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their ?1-?2 platform domain, to the intended target cell specifically. The ?1-?2 domain is contiguous with a heterologous ?3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the ?3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified ?3 domain of a MIC protein.Type: ApplicationFiled: June 20, 2014Publication date: October 9, 2014Applicant: AvidBiotics Corp.Inventors: David W. MARTIN, JR., Steven R. Williams
-
Patent number: 8796420Abstract: This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their ?1-?2 platform domain, to the intended target cell specifically. The ?1-?2 domain is contiguous with a heterologous ?3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the ?3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified ?3 domain of a MIC protein.Type: GrantFiled: July 5, 2011Date of Patent: August 5, 2014Assignee: AvidBiotics Corp.Inventors: David W. Martin, Jr., Steven R. Williams
-
Patent number: 8673553Abstract: Recombinant P4 bacteriophage containing modified tail fibers having a base plate attachment region (BPAR) from a P2 bacteriophage gene H product and a heterologous receptor binding domain (RBD) are disclosed. Methods for the use of the recombinant P4 bacteriophage, such as to detect the presence of a target bacterium in a sample, are also described.Type: GrantFiled: March 12, 2013Date of Patent: March 18, 2014Assignee: AvidBiotics CorporationInventors: Dean M. Scholl, Steven R. Williams
-
Patent number: 8673291Abstract: This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically kill Clostridium difficile bacteria, dangerous human pathogens. Also disclosed are methods of producing the R-type bacteriocins in innocuous producer cells that, unlike C. difficile, do not die in the presence of oxygen. Disclosed also is the specific gene of the isolated gene cluster that determines the killing spectrum of the R-type bacteriocin and the demonstration that the killing spectra of diffocins can be altered by engineering orf1374 of the diffocin genetic locus. This invention offers a potent bactericidal agent and a means to make it in order to kill selectively C. difficile bacteria in the environment of the gastrointestinal tract where they can cause great harm and even death of the infected patient or farm animal.Type: GrantFiled: May 27, 2011Date of Patent: March 18, 2014Assignee: AvidBiotics Corp.Inventors: Dean M. Scholl, Dana M. Gebhart, Steven R. Williams, Gregory R. Govoni, David W. Martin, Jr.
-
Patent number: 8658765Abstract: This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their ?1-?2 platform domain, to the intended target cell specifically. The ?1-?2 domain is contiguous with a heterologous ?3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the ?3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified ?3 domain of a MIC protein.Type: GrantFiled: December 30, 2010Date of Patent: February 25, 2014Assignee: AvidBiotics Corp.Inventors: David W. Martin, Jr., Steven R. Williams
-
Publication number: 20130282665Abstract: A method for archiving files includes determining when a change in an operating file is imminent, capturing the operating file immediately before the change in the operating file occurs, if the operating file has not already been captured; and capturing the operating file immediately after the change in the operating file has occurred.Type: ApplicationFiled: June 24, 2013Publication date: October 24, 2013Inventors: Warren Roach, Steven R. Williams, Troy J. Reiber, Steven C. Burdine
-
Patent number: 8473478Abstract: A method for archiving files includes determining when a change in an operating file is imminent, capturing the operating file immediately before the change in the operating file occurs, if the operating file has not already been captured; and capturing the operating file immediately after the change in the operating file has occurred.Type: GrantFiled: September 21, 2001Date of Patent: June 25, 2013Inventors: Warren Roach, Steven R. Williams, Troy J. Reiber, Steven C. Burdine
-
Patent number: 8206971Abstract: Modified forms of naturally occurring bacteriocins, such as the R-type pyocins of Pseudomonas aeruginosa, are disclosed as are methods for producing them in GRAS organisms. The bacteriocins are modified at the ends of their tail fibers in a region responsible for binding specificity and affinity to their cognate binding partners, or receptors, such as those on the surface of bacteria. Methods for the use of the modified bacteriocins, such as to bind receptors, including virulence or fitness factors, on the surfaces of bacteria, are also described.Type: GrantFiled: February 5, 2010Date of Patent: June 26, 2012Assignee: AvidBiotics CorporationInventors: Dean M. Scholl, Steven R. Williams
-
Publication number: 20110311561Abstract: This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their ?1-?2 platform domain, to the intended target cell specifically. The ?1-?2 domain is contiguous with a heterologous ?3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the ?3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified ?3 domain of a MIC protein.Type: ApplicationFiled: July 5, 2011Publication date: December 22, 2011Applicant: AvidBiotics Corp.Inventors: David W. Martin, JR., Steven R. Williams
-
Publication number: 20110293566Abstract: This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically kill Clostridium difficile bacteria, dangerous human pathogens. Also disclosed are methods of producing the R-type bacteriocins in innocuous producer cells that, unlike C. difficile, do not die in the presence of oxygen. Disclosed also is the specific gene of the isolated gene cluster that determines the killing spectrum of the R-type bacteriocin and the demonstration that the killing spectra of diffocins can be altered by engineering orf1374 of the diffocin genetic locus. This invention offers a potent bactericidal agent and a means to make it in order to kill selectively C. difficile bacteria in the environment of the gastrointestinal tract where they can cause great harm and even death of the infected patient or farm animal.Type: ApplicationFiled: May 27, 2011Publication date: December 1, 2011Applicant: AvidBiotics Corp.Inventors: Dean M. SCHOLL, Dana M. Gebhart, Steven R. Williams, Gregory R. Govoni, David W. Martin, JR.